Akèy › Kansè Poumon ki pa ti selil › Ohio › Columbus
Etid klinik pou Kansè Poumon ki pa ti selil nan Columbus, OH
56 etid pou Kansè Poumon ki pa ti selil ap chèche patisipan nan sit nan ak bò kote Columbus (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Ap rekriteFaz 3
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Health Center West, Columbus
- ak 3 plis
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Local Institution - 0176, Columbus
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Ap rekriteFaz 1
- ALX Center 10, Columbus
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Ap rekriteFaz 3
- The Ohio State University, Columbus
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Ap rekriteFaz 1/2
- The Mark H Zangmeister Center /ID# 272502, Columbus
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- The Ohio State University Comprehensive Cancer Center, Columbus
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
- OhioHealth Riverside Methodist Hospital, Columbus
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Local Institution - 0102, Columbus
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Ap rekriteFaz 2/3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus
Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
Ap rekriteFaz 1
- Ohio State University, Columbus
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Ap rekriteFaz 3
- Clinical Study Sites, Columbus
- Clinical Study Site, Columbus
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Ap rekriteFaz 2/3
- Mark H. Zangmeister Cancer Center, Columbus
Osimertinib and Tegavivint as First-Line Therapy for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Ohio State University Comprehensive Cancer Center, Columbus
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
Ap rekriteFaz 1/2
- Ohio State University, Columbus
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Ap rekriteFaz 2
- Ohio State University, Columbus
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 3
- Ohio State University, Columbus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Ap rekriteFaz 3
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer -T, Columbus
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Ohio State University Hospital, Columbus
Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
Ap rekriteFaz 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Ap rekriteFaz 3
- Ohio State University Hospitals, Columbus
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
Ap rekriteFaz 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0015), Columbus
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
Ap rekriteEtid obsèvasyon
- Ohio State University Comprehensive Cancer Center ( Site 0015), Columbus
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Ohio State University, Columbus
SMP-3124LP in Adults With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Ohio State University, Columbus
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Ap rekriteFaz 1/2
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Ap rekriteFaz 1
- Ohio State University, Columbus
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Ap rekriteFaz 1/2
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Ap rekriteFaz 1
- Local Institution - 0045, Columbus
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 3
- Ohio State University Comprehensive Cancer Center, Columbus
Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy
Ap rekriteVolontè an sante akeyi
- Ohio State University Comprehensive Cancer Center, Columbus
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- The Ohio State University (OSU) Wexner Medical Center, Columbus
Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer
Ap rekrite
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- The Ohio State University Comprehensive Cancer Center, Columbus
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Ap rekriteFaz 1
- Ohio State University, Columbus
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- Mount Carmel Grove City Hospital, Grove City · 7 mi lwen
- ak 2 plis
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Ap rekriteFaz 1/2
- The Ohio State University Wexner Medical Center, Columbus
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Ap rekriteFaz 2/3
- Columbus Oncology and Hematology Associates Inc, Columbus
- Riverside Methodist Hospital, Columbus
- Grant Medical Center, Columbus
- ak 7 plis
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Ap rekriteFaz 1/2
- Ohio State University Comprehensive Cancer Center, Columbus
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
Ap rekriteFaz 2
- Ohio State University Comprehensive Cancer Center, Columbus
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Ap rekriteEtid obsèvasyon
- Memorial Hospital, Marysville · 27 mi lwen
PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer
Ap rekriteFaz 1
- Ohio State University Comprehensive Cancer Center, Columbus
GEMINI-NSCLC: NSCLC Biomarker Study
Ap rekriteEtid obsèvasyon
- Ohio State University, Columbus
- OhioHealth Reseach Institute, Columbus
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
Ap rekriteFaz 1/2
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Columbus
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- The Ohio State University, Columbus
Etid Kansè Poumon ki pa ti selil nan lòt vil
- Houston, TX145 etid
- New York City, NY120 etid
- Arlington, VA104 etid
- Nashville, TN97 etid
- Boston, MA90 etid
- Los Angeles, CA87 etid
- St. Louis, MO73 etid
- Chicago, IL61 etid
- Baltimore, MD60 etid
- San Antonio, TX59 etid
- Washington, DC55 etid
- Seattle, WA53 etid
Lòt etid nan Columbus
- Kansè nan tete39 etid
- Kansè ovè39 etid
- Kansè (tout kalite)38 etid
- Kansè poumon37 etid
- Leksemi mieloïd egi35 etid
- Lukemi lenfositè kwonik28 etid
- Kansè Metastatik27 etid
- Kansè Endomèt25 etid
- Kansè kolorektal24 etid
- Kansè pwostat24 etid
- Myelom Miltip24 etid
- Melanom21 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.